Feb. 10, 2009 (Xinhua News Agency) -- Chindex reports results for Q3 FY 2009

BEIJING, Feb. 10 (Xinhua) ? Chindex International Inc. (NASDAQ:CHDX) (CHDX.NASDAQ), a leading supplier of Western medical products and services in China, announced Tuesday its financial results for the third quarter of fiscal year 2009.

It posted 42.6 million US dollars of revenue in Q3, up 16 percent from 36.0 million US dollars on the year.

Included are 20.5 million US dollars from the healthcare services division, up 16 percent year on year and 21.1 million US dollars from the medical products division.

Income from operations read 1.9 million US dollars, down from 3.9 million US dollars in the same quarter of last fiscal year on rising operating costs.

The company said the costs reflect expenditures for R&D, new clinics openings, additional medical personnel in its Beijing and Shanghai hospitals, rising direct patient care costs and increased medical product selling activities.

Its net income for the quarter, ended December 31, 2008, was 846,000 US dollars, or 0.05 US dollar per diluted share, compared to a net income of 3.9 million US dollars, or 0.28 per diluted share, for the quarter end one year earlier.

The diluted share price reflected the early redemption of CDs, related write offs and tax benefit, the company said.

Robert Lipson, president and CEO of Chindex, expects revenue from medical products of 50 to 55 million US dollars for the second half of fiscal 2009 on considerable product shipments in Q4. He also predicts full year revenue growth for healthcare service to be at the mid-twenty percent range.

Despite the global financial crisis, the company enjoyed strong demand for products and services, he said while upbeat over growth opportunities brought by China's healthcare reform.